Pharmacon - conference on Biosimilars

Venue: Dom omladine Beograd

Location: Belgrade, Serbia, Other

Event Date/Time: Nov 23, 2011 End Date/Time: Nov 23, 2011
Registration Date: Nov 22, 2011
Early Registration Date: Nov 10, 2011
Report as Spam

Description

Healthcare biotech is a fast growing field within modern medicine. It can play a vital role in tailoring healthcare to the individual as well as providing treatments for hitherto incurable diseases. Biologics treat rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease, uveitis, asthma, diabetes, congestive cardiac failure and multiple sclerosis.
In clinical trials, researchers are testing monoclonal antibodies to treat lymphoma, leukemia, melanoma, and cancers of the brain, breast, lung, kidney, colon, rectum, ovary, prostate, and other areas.

In the next decade, if not sooner, biologicals are expected to become the most important economic and therapeutic component of the pharmaceutical market. According to one estimate, by 2016 eight of the top 10 pharmaceutical products will be monoclonal antibodies or recombinant products. (Source: Ohly and Patel, Journal of Intellectual Property Law and Practice)

Biosimilars (similar biological medicinal products or follow-on biologics) have increasingly important role in the life sciences industry. According to GBI Research the global market for biosimilars is valued at $243.8m in 2009 and is expected to increase to $4,697m in 2016 at a compound annual growth rate (CAGR) of 52.6%. The market is expected to gather momentum after the launch of biosimilar monoclonal antibodies.

The expected price reduction for a biosimilar is not more than 10% to 30% than that of the original biological. Yet, according to EGA, the improved affordability of healthcare that could result from the use of biosimilar medicines is real. As an example, the EPO biosimilar introduction in Germany resulted in EUR 60m annual savings (-17, 3%) in the first year of the market. It has been estimated that biosimilars in Germany alone could contribute to 1 billion EUR annual savings from 2017. By 2020 the savings through biosimilars would be more than 8 billion EUR.

Learn more at the Pharmacon conference on Biosimilars:

• What are biosimilar medicenes?
• What makes biotechnology medicinal products different?
• Challenges in commercialisation of biosimilars
• How is licensing of biosimilars actually being applied in Europe?
• Biosimilar regulatory timeline from legislation to approval
• Legal environment for biosimilar medicines
• What new technologies/systems are driving forward bioproducts?
• Monoclonal Antibodies - taking biosimilar medicines to the next level
• Biosimilar products safety – requirements and main concerns
• What doctors should know about biosimilars?
• What are the obstacles to increased use?

Who is Pharmacon on biosimilars made for?

PHARMACON is an ideal opportunity for professionals in the pharmaceutical and biotech industries who work on clinical development, process development, safety and quality assurance, regulatory compliance, legal affairs and corporate strategic planning, doctors, public health sector representatives, wholesalers, brand managers, sales managers, PR managers, investors, consultants, lawyers, to learn more about these issues, make new contacts and exchange experience.

Venue

Makedonska 22
Belgrade
Serbia
Other
MORE INFO ON THIS VENUE

Additional Information

Register online: http://pharmacon.rs/biosimilars2011/register.php

Types